<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002787</url>
  </required_header>
  <id_info>
    <org_study_id>1104.00</org_study_id>
    <secondary_id>NCI-2012-00669</secondary_id>
    <nct_id>NCT00002787</nct_id>
  </id_info>
  <brief_title>Vaccine Therapy in Treating Patients With Multiple Myeloma Who Have Undergone Stem Cell Transplantation</brief_title>
  <official_title>Phase I Trial of Post Transplant Immunization With Autologous Myeloma Idiotype-KLH/GM-CSF In Myeloma Patients Following Autologous or Allogeneic Marrow or Stem Cell Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Fred Hutchinson Cancer Center</source>
  <brief_summary>
    <textblock>
      The purpose of this trial is to test the safety and immune response to four immunizations&#xD;
      with this vaccine made from a protein produced by the patient's tumor. There is no guarantee&#xD;
      or promise that this procedure will be successful&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. To determine the safety of multiple subcutaneous vaccinations with myeloma Id-KLH&#xD;
      (idiotype-keyhole limpet hemocyanin) with GM-CSF (sargramostim) in post allogeneic transplant&#xD;
      myeloma patients, or with GM-CSF +/- interleukin (IL)-2 (aldesleukin) in post autologous&#xD;
      transplant myeloma patients.&#xD;
&#xD;
      II. To evaluate patients pre and post bone marrow transplantation (BMT) for evidence of&#xD;
      endogenous idiotype specific immune response.&#xD;
&#xD;
      III. To characterize the time course, specificity and persistence of antibody and T cell&#xD;
      immune response to myeloma idiotype and to KLH induced by myeloma Ig (Id) immunization.&#xD;
&#xD;
      IV. To clone, expand and characterize T cells specific for the tumor idiotype. V. Monitor&#xD;
      myeloma involvement in bone marrow and serum paraprotein level following vaccination.&#xD;
&#xD;
      VI. Use stored patient samples to clone, expand, and characterize T cells specific for&#xD;
      myeloma antigens other than idiotype and identify the antigens they recognize so that they&#xD;
      can be used in future studies.&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
      Patients receive autologous immunoglobulin idiotype-KLH conjugate vaccine combined with&#xD;
      sargramostim subcutaneously (SC) in weeks 0, 2, 6, and 10 and sargramostim SC once daily (QD)&#xD;
      for three days following each vaccine injection. Some patients also receive aldesleukin SC&#xD;
      daily from weeks 2-14.&#xD;
&#xD;
      After completion of study treatment, patients are followed up every 3 months for 1 year and&#xD;
      then every 6 months for 1 year.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 1996</start_date>
  <primary_completion_date type="Actual">December 2002</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Toxicities graded using the National Cancer Institute (NCI) Common Toxicity Criteria</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Descriptive statistics will be used to summarize changes from baseline in clinical laboratory parameters for each cohort.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Immune response</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Descriptive statistics will be used to summarize changes from baseline in clinical laboratory parameters for each cohort.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>Refractory Multiple Myeloma</condition>
  <condition>Stage I Multiple Myeloma</condition>
  <condition>Stage II Multiple Myeloma</condition>
  <condition>Stage III Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>Treatment (vaccine therapy)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive autologous immunoglobulin idiotype-KLH conjugate vaccine combined with sargramostim SC in weeks 0, 2, 6, and 10 and sargramostim SC QD for three days following each vaccine injection. Some patients also receive aldesleukin SC daily from weeks 2-14.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>autologous immunoglobulin idiotype-KLH conjugate vaccine</intervention_name>
    <description>Given SC</description>
    <arm_group_label>Treatment (vaccine therapy)</arm_group_label>
    <other_name>autologous immunoglobulin idiotype-keyhole limpet hemocyanin conjugate vaccine</other_name>
    <other_name>GTOP-99</other_name>
    <other_name>Id-KLH</other_name>
    <other_name>Id-KLH conjugate vaccine</other_name>
    <other_name>recombinant Id-KLH</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>sargramostim</intervention_name>
    <description>Given SC</description>
    <arm_group_label>Treatment (vaccine therapy)</arm_group_label>
    <other_name>GM-CSF</other_name>
    <other_name>Leukine</other_name>
    <other_name>Prokine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>aldesleukin</intervention_name>
    <description>Given SC</description>
    <arm_group_label>Treatment (vaccine therapy)</arm_group_label>
    <other_name>IL-2</other_name>
    <other_name>Proleukin</other_name>
    <other_name>recombinant human interleukin-2</other_name>
    <other_name>recombinant interleukin-2</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (vaccine therapy)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  ELIGIBILITY FOR VACCINE PREPARATION:&#xD;
&#xD;
          -  Patients must have a diagnosis of multiple myeloma and be eligible for a Fred&#xD;
             Hutchinson Cancer Research Center (FHCRC) treatment protocol using high dose therapy&#xD;
             with syngeneic, allogeneic or autologous marrow or stem cell transplantation&#xD;
&#xD;
          -  Pretransplant sera available with immunoglobulin A (IgA), immunoglobulin D (IgD),&#xD;
             immunoglobulin E (IgE), immunoglobulin G (IgG), or immunoglobulin M (IgM) monoclonal&#xD;
             paraprotein with a level of 1.5 grams/dl or greater identifiable on serum protein&#xD;
             electrophoresis; eligibility for patients with pretransplant paraprotein levels of&#xD;
             less than 1.5 gm/dl will be evaluated on an individual basis to determine whether&#xD;
             purification of idiotype is feasible&#xD;
&#xD;
          -  ELIGIBILITY FOR POST-TRANSPLANT IDIOTYPE VACCINATION:&#xD;
&#xD;
          -  Successful isolation and production of an autologous idiotype vaccine from pre-BMT&#xD;
             sera&#xD;
&#xD;
          -  Greater than 60 days post BMT&#xD;
&#xD;
          -  Achievement of a partial remission or greater (more than 75% reduction in serum&#xD;
             paraprotein) for patients transplanted in relapse&#xD;
&#xD;
          -  Stable absolute neutrophil count (ANC) &gt; 1000&#xD;
&#xD;
          -  Platelet count &gt; 50,000 not requiring transfusions or growth factors&#xD;
&#xD;
          -  Red blood cell (RBC) supportable to hematocrit (Hct) &gt; 25 with less than 2 units of&#xD;
             packed red blood cell (PRBC)/week&#xD;
&#xD;
          -  Treatment with a stable dose of Interferon is allowed&#xD;
&#xD;
          -  Karnofsky status &gt; 60 percent&#xD;
&#xD;
          -  Immunosuppression:&#xD;
&#xD;
               -  Off all corticosteroids&#xD;
&#xD;
               -  Either off all immunosuppressive medications or on a stable/tapering dose of&#xD;
                  cyclosporin or FK506 only&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Graft-vs-host disease requiring treatment with corticosteroids&#xD;
&#xD;
          -  Serum creatinine &gt; 3.0&#xD;
&#xD;
          -  Uncontrolled infection&#xD;
&#xD;
          -  Disease progression&#xD;
&#xD;
          -  Presence of medical complication that in the opinion of the investigators would result&#xD;
             in inability to tolerate the vaccination protocol&#xD;
&#xD;
          -  Patients with a history of serious adverse reactions to GM-CSF&#xD;
&#xD;
          -  Patients with a history of serious adverse reactions to IL-2 will not receive&#xD;
             concurrent IL-2 administration but may receive the Id-KLH vaccine with GM-CSF&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Maloney</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>May 20, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 21, 2004</study_first_posted>
  <last_update_submitted>May 2, 2019</last_update_submitted>
  <last_update_submitted_qc>May 2, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 6, 2019</last_update_posted>
  <responsible_party>
    <name_title>Maloney, David</name_title>
    <organization>Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aldesleukin</mesh_term>
    <mesh_term>Interleukin-2</mesh_term>
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Immunoglobulins, Intravenous</mesh_term>
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Sargramostim</mesh_term>
    <mesh_term>Keyhole-limpet hemocyanin</mesh_term>
    <mesh_term>Immunoglobulin Idiotypes</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

